Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025

Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

WQWenxin QiYZYuqi ZhangXHXiaoyu Hao

Discussion

Loading...

Member takes

Overview

Systematic review found comparable responses in CAR-T patients, yet TP53 mutations indicate poorer survival outcomes.

Key Points

  • Patients with TP53 mutations showed shorter progression-free survival and overall survival than wild type patients receiving CAR-T therapy.
  • Overall response rates were similar between wild type and TP53-mutation groups, indicating potential efficacy.
  • The analysis included 848 patients across 10 studies, highlighting the importance of treatment variation.
  • Dual-targeting CAR-T therapy may improve outcomes for TP53m patients compared to traditional single targeting.

Cite This Study

Qi et al. (2025) studied this question.

synapsesocial.com/papers/68d5d12cddad3c16d46363c4https://doi.org/10.1111/jcmm.70818
View Full Paper
Ask AI
Bookmark
Share